Research Articles published by eLife are full-length studies that present important breakthroughs across the life sciences and biomedicine. There is no maximum length and no limits on the number of display items.
Projection-specific optogenetic and chemogenetic experiments reveal a hippocampal-lateral septal pathway that potentially acts via the ventral tegmental area to regulate social novelty preference behaviors.
JeYoung Jung, Steve Williams, Matthew A Lambon Ralph
GABAergic inhibition in the anterior temporal lobe shapes semantic memory and its neuroplasticity through a non-linear relationship, revealing a neurochemical basis for individual differences.
Drug synergy Interaction Prediction improves personalized drug synergy prediction by utilizing drug-specific pathway activation scores to predict personalized drug synergy and reveals mechanistic pathways underlying synergistic effects.
Functional analyses reveal the HNF4α-TET2-FBP1 axis as a critical regulator of gluconeogenesis, type 2 diabetes (T2D) progression, and metformin’s therapeutic effects, which proposes TET2 as a promising therapeutic target for T2D.
Ethan S Benevides, Prajwal P Thakre ... David D Fuller
DREADD-mediated activation of phrenic motor output produces sustained increases in diaphragm activity and tidal volume, highlighting a potential strategy to restore breathing in clinical conditions associated with impaired diaphragm activation.
Diana M Karosas, Leslie Gonzales ... Kenneth S Henry
Otoacoustic emissions recorded noninvasively from the ear canal accurately predict cochlear frequency tuning in an avian species, in contrast to previously tested classical behavioral methods.
The drug-phospholipid interaction is fully elucidated at molecular level as an important part of the mode of action of daptomycin and the mechanism of its resistance in bacterial pathogens.
Integrated single-cell RNA-seq analysis identifies ferroptosis-driven tumor microenvironment features, enabling a prognostic risk model and therapeutic targets to advance precision medicine for triple-negative breast cancer.
